Alla Yu. Savchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alla Yu. Savchenko has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Galina Vladislavovna Ramenskaya
I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)
9 shared publications - Evgenii I. Balakin
Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia
4 shared publications - Igor E. Shokhin
Limited Liability Company "Center of Pharmaceutical Analytics" (LLC "CPHA"); National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
4 shared publications - M. S. Burenkov
AO Pharm-Sintez
4 shared publications - Vladimir P. Skulachev
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
4 shared publications - Andrey A. Zamyatnin
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
3 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 2 (3) , 254-268
Oligonucleotide Adjuvants in Vaccinology: Current Classification, Mechanisms of Action, and Development Trends
Introduction. Modern vaccines require adjuvants that can induce not only a humoral immune response but also a cellular one. CpG oligonucleotides are among the most promising candidates. They are synthetic TLR9 agonists that imitate bacterial DNA. Despite the approval of products such as HEPLISAV-B® and SpikoGen®, information on the classification, mechanisms of action, and modification strategies of CpG adjuvants remains fragmented. This review aims to systematise current data on CpG oligonucleotide adjuvants, including their structure–function characteristics, chemical modifications, and delivery strategies. Materials and methods. A review of the scientific literature indexed in PubMed, PubMed Central, and eLibrary was conducted. The search covered a 20-year period, reflecting the availability of seminal studies on CpG-mediated immunostimulation published in the early 2000s. In addition, recent publications from the past 5–7 years were selected to assess current trends. The search strategy included the following keywords: CpG oligonucleotides, TLR9 agonists, vaccine adjuvants, oligonucleotide synthesis, and phosphorothioate modifications. Results. The major classes of adjuvants were systematically reviewed, and the position of oligonucleotides within the overall classification was defined. CpG oligonucleotides of classes A, B, C, and P were characterised in detail, with particular attention to their structural features and immunological profiles. Phosphorothioate backbone modifications were shown to be critical for improving the stability and efficacy of CpG oligonucleotides. The main barriers to the broader use of CpG adjuvants were identified as targeted delivery challenges and potential reactogenicity. Current strategies to overcome these limitations were analysed, including ligand conjugation, such as GalNAc, encapsulation in nanoparticles, including liposomes, PLGA, metallic nanoparticles, and hybrid OMV-based platforms, as well as incorporation into combined adjuvant systems. Discussion and conclusion. The most promising directions for future research include optimising the chemical structure of CpG oligonucleotides to improve their pharmacokinetic properties; developing targeted delivery systems, including nanoscale carriers and ligand conjugates; incorporating CpG oligonucleotides into multicomponent adjuvant systems to achieve synergistic effects; and applying them in cancer immunology to reprogramme tumour-associated macrophages and overcome resistance to immune checkpoint inhibitors. Further research in this field may pave the way for the development of next-generation vaccines against socially significant infectious diseases and cancer.
- 18 September 2026
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 2 (3) , 254-268
Open AccessOligonucleotide Adjuvants in Vaccinology: Current Classification, Mechanisms of Action, and Development Trends
Introduction. Modern vaccines require adjuvants that can induce not only a humoral immune response but also a cellular one. CpG oligonucleotides are among the most promising candidates. They are synthetic TLR9 agonists that imitate bacterial DNA. Despite the approval of products such as HEPLISAV-B® and SpikoGen®, information on the classification, mechanisms of action, and modification strategies of CpG adjuvants remains fragmented. This review aims to systematise current data on CpG oligonucleotide adjuvants, including their structure–function characteristics, chemical modifications, and delivery strategies. Materials and methods. A review of the scientific literature indexed in PubMed, PubMed Central, and eLibrary was conducted. The search covered a 20-year period, reflecting the availability of seminal studies on CpG-mediated immunostimulation published in the early 2000s. In addition, recent publications from the past 5–7 years were selected to assess current trends. The search strategy included the following keywords: CpG oligonucleotides, TLR9 agonists, vaccine adjuvants, oligonucleotide synthesis, and phosphorothioate modifications. Results. The major classes of adjuvants were systematically reviewed, and the position of oligonucleotides within the overall classification was defined. CpG oligonucleotides of classes A, B, C, and P were characterised in detail, with particular attention to their structural features and immunological profiles. Phosphorothioate backbone modifications were shown to be critical for improving the stability and efficacy of CpG oligonucleotides. The main barriers to the broader use of CpG adjuvants were identified as targeted delivery challenges and potential reactogenicity. Current strategies to overcome these limitations were analysed, including ligand conjugation, such as GalNAc, encapsulation in nanoparticles, including liposomes, PLGA, metallic nanoparticles, and hybrid OMV-based platforms, as well as incorporation into combined adjuvant systems. Discussion and conclusion. The most promising directions for future research include optimising the chemical structure of CpG oligonucleotides to improve their pharmacokinetic properties; developing targeted delivery systems, including nanoscale carriers and ligand conjugates; incorporating CpG oligonucleotides into multicomponent adjuvant systems to achieve synergistic effects; and applying them in cancer immunology to reprogramme tumour-associated macrophages and overcome resistance to immune checkpoint inhibitors. Further research in this field may pave the way for the development of next-generation vaccines against socially significant infectious diseases and cancer.
- Open Access
- 9 September 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (3) , 86-98
Current approaches to paclitaxel formulation development: challenges and future perspectives (review)
Introduction. Paclitaxel is a plant-derived antineoplastic agent with high potential in the treatment a wide range of malignant neoplasms. However, the unique properties of paclitaxel – low aqueous solubility, poor oral bioavailability, and high toxicity – create considerable challenges in the development of stable formulations, substantially limiting its clinical application. Therefore, there is an active ongoing search for novel technologies capable of enhancing the therapeutic efficacy of paclitaxel while reducing the impact of toxic effects on the human body. Text. Paclitaxel is one of the most widely used drugs for the treatment in modern oncology. Its antitumor mechanism of action is based on its ability to act on tubulin, stimulating the assembly of microtubules, stabilizing them, and thus preventing their dissociation, which leads to mitotic arrest and subsequent cell death. Paclitaxel possesses a complex structure comprising various functional groups, including ester linkages, a taxane ring, and aromatic moieties. These molecular elements determine paclitaxel's anticancer activity as well as its physicochemical properties. Paclitaxel belongs to Class IV according to the Biopharmaceutics Classification System (BCS) and has low solubility and low intestinal permeability. Drug substances of this class are the most challenging for formulation development and exhibit extremely low bioavailability. The low solubility, poor bioavailability, and high toxicity of paclitaxel pose significant challenges in pharmaceutical development. Furthermore, the polymorphism of paclitaxel can also have a significant influence on stability and biopharmaceutical properties of finished dosage forms. For example, the choice of polymorphic form can be of fundamental importance for the efficacy and safety not only of antitumor drugs but also of paclitaxel coated medical devices used in the treatment of cardiovascular diseases, in particular restenosis after angioplasty. Despite the availability of formulations successfully used in clinical practice, the development of new ones continues to this day. Nowadays, researchers face the task of enhancing paclitaxel's bioavailability while reducing its toxic effects on the human body. Conclusion. The challenges in developing paclitaxel formulations are multifaceted. New strategies for treating malignant tumors using paclitaxel are in place, and novel drug compositions and combinations are under investigation. This work reviews contemporary studies focused on the development of new dosage forms of paclitaxel.
- 9 September 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (3) , 86-98
Open AccessCurrent approaches to paclitaxel formulation development: challenges and future perspectives (review)
Introduction. Paclitaxel is a plant-derived antineoplastic agent with high potential in the treatment a wide range of malignant neoplasms. However, the unique properties of paclitaxel – low aqueous solubility, poor oral bioavailability, and high toxicity – create considerable challenges in the development of stable formulations, substantially limiting its clinical application. Therefore, there is an active ongoing search for novel technologies capable of enhancing the therapeutic efficacy of paclitaxel while reducing the impact of toxic effects on the human body. Text. Paclitaxel is one of the most widely used drugs for the treatment in modern oncology. Its antitumor mechanism of action is based on its ability to act on tubulin, stimulating the assembly of microtubules, stabilizing them, and thus preventing their dissociation, which leads to mitotic arrest and subsequent cell death. Paclitaxel possesses a complex structure comprising various functional groups, including ester linkages, a taxane ring, and aromatic moieties. These molecular elements determine paclitaxel's anticancer activity as well as its physicochemical properties. Paclitaxel belongs to Class IV according to the Biopharmaceutics Classification System (BCS) and has low solubility and low intestinal permeability. Drug substances of this class are the most challenging for formulation development and exhibit extremely low bioavailability. The low solubility, poor bioavailability, and high toxicity of paclitaxel pose significant challenges in pharmaceutical development. Furthermore, the polymorphism of paclitaxel can also have a significant influence on stability and biopharmaceutical properties of finished dosage forms. For example, the choice of polymorphic form can be of fundamental importance for the efficacy and safety not only of antitumor drugs but also of paclitaxel coated medical devices used in the treatment of cardiovascular diseases, in particular restenosis after angioplasty. Despite the availability of formulations successfully used in clinical practice, the development of new ones continues to this day. Nowadays, researchers face the task of enhancing paclitaxel's bioavailability while reducing its toxic effects on the human body. Conclusion. The challenges in developing paclitaxel formulations are multifaceted. New strategies for treating malignant tumors using paclitaxel are in place, and novel drug compositions and combinations are under investigation. This work reviews contemporary studies focused on the development of new dosage forms of paclitaxel.
- Open Access
- 6 July 2026
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (2) , 207-215
Coring of Injectable Dosage Forms: Risk Minimization Strategies (Review)
INTRODUCTION. Contamination of injection and infusion preparations in the vials with fragments of a punctured stopper (coring) poses direct risks of microembolism, inflammatory reactions in patients, and dosing errors. No risk minimization strategy for coring of a punctured stopper currently exists in the Russian Federation. AIM. This study aimed to determine the ways to minimize contamination risk of an injectable drug with particles of a vial stopper punctured by a needle. DISCUSSION . Standardized puncturing technique for vial stoppers was found to be a fundamental preventative measure: puncturing at an angle of 45–60º, followed by a right angle, with the bevel facing upwards, significantly reduces the risk of a fragmented stopper. Using small-gauge needles (≥20G) and restricting the number of punctures (as few as possible and at least 0.75 mm apart) also minimized coring. Filter needles that trap the resulting particles were substantiated as a reliable technological solution, as well as choosing closed-loop transfer systems and prefilled single-use syringes that prevents any stopper manipulations. The important elements of the strategy include a thorough visual inspection of each dose against a dark background under intense light and training medical personnel to puncture the vials using simulation techniques. CONCLUSIONS. Based on the references, the strategy offered to minimize the risks associated with the vial stopper fragmentation at injection and infusion integrates technological, methodological, and organizational solutions. For practical implementation, it is recommended to standardize the puncturing technique of the vial stopper; to train medical personnel in puncturing techniques that reduce the risk of forming stopper particles; to visually inspect each dose of the drug before administration; and to use specific medical devices that prevent manipulations with the vial stopper.
- 6 July 2026
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (2) , 207-215
Open AccessCoring of Injectable Dosage Forms: Risk Minimization Strategies (Review)
INTRODUCTION. Contamination of injection and infusion preparations in the vials with fragments of a punctured stopper (coring) poses direct risks of microembolism, inflammatory reactions in patients, and dosing errors. No risk minimization strategy for coring of a punctured stopper currently exists in the Russian Federation. AIM. This study aimed to determine the ways to minimize contamination risk of an injectable drug with particles of a vial stopper punctured by a needle. DISCUSSION . Standardized puncturing technique for vial stoppers was found to be a fundamental preventative measure: puncturing at an angle of 45–60º, followed by a right angle, with the bevel facing upwards, significantly reduces the risk of a fragmented stopper. Using small-gauge needles (≥20G) and restricting the number of punctures (as few as possible and at least 0.75 mm apart) also minimized coring. Filter needles that trap the resulting particles were substantiated as a reliable technological solution, as well as choosing closed-loop transfer systems and prefilled single-use syringes that prevents any stopper manipulations. The important elements of the strategy include a thorough visual inspection of each dose against a dark background under intense light and training medical personnel to puncture the vials using simulation techniques. CONCLUSIONS. Based on the references, the strategy offered to minimize the risks associated with the vial stopper fragmentation at injection and infusion integrates technological, methodological, and organizational solutions. For practical implementation, it is recommended to standardize the puncturing technique of the vial stopper; to train medical personnel in puncturing techniques that reduce the risk of forming stopper particles; to visually inspect each dose of the drug before administration; and to use specific medical devices that prevent manipulations with the vial stopper.
- Open Access
- 10 April 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Mathematical pharmacokinetics modeling of parenteral depot formulations
Introduction. The development of parenteral depot formulations of drugs with modified release is a critical area in the treatment of chronic diseases such as cancer, schizophrenia, and diabetes. These formulations improve treatment adherence, maintain stable plasma concentrations, and reduce the frequency of injections. However, their development is fraught with technological and pharmacokinetic challenges, including nonlinear release of the active ingredient and high interindividual variability. Aim. To systematically analyze and summarize current methodological approaches to mathematical modeling of the pharmacokinetics of parenteral long-acting drug formulations. Materials and methods. A targeted literature search was conducted in PubMed, Google Scholar, and Scopus for the period 2015–2025 using Boolean operators and combinations of relevant keywords. The review includes data on clinically used long-acting parenteral formulations as well as on polymeric carriers (PLGA, hydrogels, in situ gels, and hybrid systems). To illustrate instrumental approaches, we consider compartmental PK models, PBPK models, and models based on machine learning methods. Results and discussion. The characteristic features of pharmacokinetic profiles of parenteral depot formulations are summarized, including the phases of initial burst, lag phase, controlled release, and late decay, as well as their relationship with the physicochemical properties of the carrier and the drug substance. The variability of the profile is shown to be associated with a combination of technological parameters (particle size, polymer composition and architecture), injection site and route of administration, and individual patient characteristics. The capabilities of nonlinear mixed-effects models, PBPK approaches, and machine learning-based models are demonstrated for describing inter- and intraindividual variability, performing simulations of dosing regimens, and supporting in silico optimization of formulation development. A basic system of ordinary differential equations (ODEs) is proposed that reflects sequential release from different depot fractions followed by distribution and elimination of the drug. Conclusion. Pharmacokinetic modeling of parenteral long-acting formulations is a key instrument within the MIDD (Model-Informed Drug Development) concept, enabling integration of mechanistic knowledge on release, absorption, and distribution with clinical data. The proposed basic ODE model structure can serve as a methodological framework for developing and adapting models for specific drug products, thereby supporting optimization of formulation composition and dosing regimens and reducing the extent of costly in vivo studies.
- 10 April 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessMathematical pharmacokinetics modeling of parenteral depot formulations
Introduction. The development of parenteral depot formulations of drugs with modified release is a critical area in the treatment of chronic diseases such as cancer, schizophrenia, and diabetes. These formulations improve treatment adherence, maintain stable plasma concentrations, and reduce the frequency of injections. However, their development is fraught with technological and pharmacokinetic challenges, including nonlinear release of the active ingredient and high interindividual variability. Aim. To systematically analyze and summarize current methodological approaches to mathematical modeling of the pharmacokinetics of parenteral long-acting drug formulations. Materials and methods. A targeted literature search was conducted in PubMed, Google Scholar, and Scopus for the period 2015–2025 using Boolean operators and combinations of relevant keywords. The review includes data on clinically used long-acting parenteral formulations as well as on polymeric carriers (PLGA, hydrogels, in situ gels, and hybrid systems). To illustrate instrumental approaches, we consider compartmental PK models, PBPK models, and models based on machine learning methods. Results and discussion. The characteristic features of pharmacokinetic profiles of parenteral depot formulations are summarized, including the phases of initial burst, lag phase, controlled release, and late decay, as well as their relationship with the physicochemical properties of the carrier and the drug substance. The variability of the profile is shown to be associated with a combination of technological parameters (particle size, polymer composition and architecture), injection site and route of administration, and individual patient characteristics. The capabilities of nonlinear mixed-effects models, PBPK approaches, and machine learning-based models are demonstrated for describing inter- and intraindividual variability, performing simulations of dosing regimens, and supporting in silico optimization of formulation development. A basic system of ordinary differential equations (ODEs) is proposed that reflects sequential release from different depot fractions followed by distribution and elimination of the drug. Conclusion. Pharmacokinetic modeling of parenteral long-acting formulations is a key instrument within the MIDD (Model-Informed Drug Development) concept, enabling integration of mechanistic knowledge on release, absorption, and distribution with clinical data. The proposed basic ODE model structure can serve as a methodological framework for developing and adapting models for specific drug products, thereby supporting optimization of formulation composition and dosing regimens and reducing the extent of costly in vivo studies.
- Open Access
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 210-219
Simulation of pharmacokinetic parameters of thiozonide in patients with low body weight based on a population pharmacokinetic model
Introduction. Patients diagnosed with pulmonary tuberculosis with multidrug-resistant or extensively drug-resistant pathogens (MDR-/XDR-TB) are characterized by reduced body weight (1, 2, 3). Under standard dosing regimens of antitubercular drugs, this can lead to altered pharmacokinetic parameters, increasing the risk of adverse reactions or reduced therapeutic efficacy. Therefore, mathematical modeling of the effect of body weight on the pharmacokinetics of the new domestic drug thiozonide is relevant for substantiating optimal dosing regimens. Aim. To develop a mathematical model for assessing the influence of body weight on the pharmacokinetic parameters of thiozonide and to analyze the modeling results for individualized dosing approaches. Materials and methods. The Julia programming environment and the Pumas.jl package were used for modeling. A two-compartment pharmacokinetic model with first-order kinetics and absorption, modified by the Weibull function, was developed. For each scenario, groups of patients with different fixed body weights (40, 50, 60, 70, and 80 kg) were considered, and 10 000 simulations were performed. Results and discussion. Analysis of the simulation results showed that the maximum drug concentration (C max ) increased as body weight decreased; however, the maximum relative difference between the extreme groups (40 and 80 kg) was 17,08 %. Minimum concentrations (C tau ) remained stable across all groups, showing relative changes of less than 2,5 %. The area under the concentration-time curve (AUC tau ) varied from 2,88 to 7,23 %. Conclusion. The study confirmed that there is no need to adjust the dosing regimen of thiozonide for patients weighing 40 to 80 kg.
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 210-219
Open AccessSimulation of pharmacokinetic parameters of thiozonide in patients with low body weight based on a population pharmacokinetic model
Introduction. Patients diagnosed with pulmonary tuberculosis with multidrug-resistant or extensively drug-resistant pathogens (MDR-/XDR-TB) are characterized by reduced body weight (1, 2, 3). Under standard dosing regimens of antitubercular drugs, this can lead to altered pharmacokinetic parameters, increasing the risk of adverse reactions or reduced therapeutic efficacy. Therefore, mathematical modeling of the effect of body weight on the pharmacokinetics of the new domestic drug thiozonide is relevant for substantiating optimal dosing regimens. Aim. To develop a mathematical model for assessing the influence of body weight on the pharmacokinetic parameters of thiozonide and to analyze the modeling results for individualized dosing approaches. Materials and methods. The Julia programming environment and the Pumas.jl package were used for modeling. A two-compartment pharmacokinetic model with first-order kinetics and absorption, modified by the Weibull function, was developed. For each scenario, groups of patients with different fixed body weights (40, 50, 60, 70, and 80 kg) were considered, and 10 000 simulations were performed. Results and discussion. Analysis of the simulation results showed that the maximum drug concentration (C max ) increased as body weight decreased; however, the maximum relative difference between the extreme groups (40 and 80 kg) was 17,08 %. Minimum concentrations (C tau ) remained stable across all groups, showing relative changes of less than 2,5 %. The area under the concentration-time curve (AUC tau ) varied from 2,88 to 7,23 %. Conclusion. The study confirmed that there is no need to adjust the dosing regimen of thiozonide for patients weighing 40 to 80 kg.
- Open Access
- 19 December 2025
- Published by SCEEMP in Regulatory Research and Medicine Evaluation
- Vol. 15 (6) , 630-641
Neural Network Technologies in Drug Registration: Computerised Analysis of Documents and Real-Time Systems
INTRODUCTION. Current methods of handling medicine regulatory documents are associated with high time cost (40-60% of labour hours), frequent documentation errors, and limited data interoperability. Neural network technologies have enabled the enhanced document preparation and a transition to full automation of the registration dossier life cycle. AIM. This study aimed to evaluate the possibility of using artificial intelligence (AI) systems in preparing a drug registration dossier. DISCUSSION. Natural language processing (NLP) models demonstrate high efficiency for the regulatory documentation. Named entity recognition (NER) systems with 89–96% entity extraction accuracy rate reduces the processing (preparation and quality review) time for documents within electronic Common Technical Document (eCTD) by 64%, but face limitations in interpreting morphologically complex terms and require annotated datasets. Without additional fine-tuning, generative models such as GPT-4, are prone to generating inaccurate facts when used in the Retrieval-Augmented Generation (RAG) architecture. Predictive systems based on graph neural networks and XGBoost ensembles demonstrate high accuracy (ROC AUC up to 0.88) when predicting drug approval; however, they cannot interpret decisions and data systematic biases. Developing document-centric platforms with NLP reduces the dossier preparation time by 60%, still, implementing an automated procedure for generating dossier sections requires an expert verification. CONCLUSIONS. The concept of integrated AI systems proves its effectiveness by reducing the document handling time by manufacturers and increasing the accuracy of decisions, which in turn speeds up the market launch of medicinal products. The prospects of introducing digital technologies are associated with overcoming definitions differences through unified ontologies. Practical implementation requires the development of unified standards for the validation of AI algorithms and adaptive systems.
- 19 December 2025
- Published by SCEEMP in Regulatory Research and Medicine Evaluation
- Vol. 15 (6) , 630-641
Open AccessNeural Network Technologies in Drug Registration: Computerised Analysis of Documents and Real-Time Systems
INTRODUCTION. Current methods of handling medicine regulatory documents are associated with high time cost (40-60% of labour hours), frequent documentation errors, and limited data interoperability. Neural network technologies have enabled the enhanced document preparation and a transition to full automation of the registration dossier life cycle. AIM. This study aimed to evaluate the possibility of using artificial intelligence (AI) systems in preparing a drug registration dossier. DISCUSSION. Natural language processing (NLP) models demonstrate high efficiency for the regulatory documentation. Named entity recognition (NER) systems with 89–96% entity extraction accuracy rate reduces the processing (preparation and quality review) time for documents within electronic Common Technical Document (eCTD) by 64%, but face limitations in interpreting morphologically complex terms and require annotated datasets. Without additional fine-tuning, generative models such as GPT-4, are prone to generating inaccurate facts when used in the Retrieval-Augmented Generation (RAG) architecture. Predictive systems based on graph neural networks and XGBoost ensembles demonstrate high accuracy (ROC AUC up to 0.88) when predicting drug approval; however, they cannot interpret decisions and data systematic biases. Developing document-centric platforms with NLP reduces the dossier preparation time by 60%, still, implementing an automated procedure for generating dossier sections requires an expert verification. CONCLUSIONS. The concept of integrated AI systems proves its effectiveness by reducing the document handling time by manufacturers and increasing the accuracy of decisions, which in turn speeds up the market launch of medicinal products. The prospects of introducing digital technologies are associated with overcoming definitions differences through unified ontologies. Practical implementation requires the development of unified standards for the validation of AI algorithms and adaptive systems.
- Open Access
- 12 September 2025
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 103 (4) , 75-81
Evaluation of Safety of Thiosonide in Multiple Doses in Patients with Multidrug, Pre-extensively or Extensively Drug-Resistant Pulmonary Tuberculosis: a Multicenter Randomized Controlled Study
The objective: to evaluate safety of Thiosonide in multiple doses, a new domestic anti-tuberculosis drug, in patients with multidrug, pre-extensively or extensively drug-resistant pulmonary tuberculosis.Subjects and Methods. The safety of Thiosonide was assessed from November 24, 2014 to May 17, 2019 within a multicenter, 12-week, double-blind, randomized, placebo-controlled clinical study (Protocol no. TIO22, Permit no. 661 dated November 24, 2014 by the Russian Ministry of Health). The study included 160 patients aged 18 to 60 years, who were undergoing inpatient or outpatient treatment in 13 clinical centers with the verified diagnosis of MDR TB, pre-XDR TB and XDR TB. Against the background of standard anti-tuberculosis therapy, patients received 200, 400 or 600 mg of Thiosonide or placebo once a day. Treatment duration made 84 days. The following parameters were used to assess safety of the drug: frequency and severity of adverse events (AEs) and serious adverse events (SAEs), number of cases of early discontinuation of the drug due AEs and SAEs, changes in vital signs during a physical examination, abnormal parameters of laboratory and instrumental tests and examinations.Results. It has been demonstrated that Thiosonide is well-tolerated and safe. During the study, 100 AEs were reported, but only one of them (1%), which was an elevated creatine phosphokinase level, was definitely related to the investigated drug. Statistical analysis reveal no significant relationship between the frequency of AEs and dosage of the drug.Conclusion. A safety study of Thiosonide, an original anti-tuberculosis drug, in patients with MDR, pre-XDR and XDR pulmonary TB with multiple administration in doses of 200 mg, 400 mg and 600 mg showed its good tolerability, accompanied by single AEs, of which no more than 1% were definitely related to the investigated drug. Due to the above, Thiosonide can be considered as a promising drug for the treatment of MDR/XDR TB patients.
- 12 September 2025
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 103 (4) , 75-81
Open AccessEvaluation of Safety of Thiosonide in Multiple Doses in Patients with Multidrug, Pre-extensively or Extensively Drug-Resistant Pulmonary Tuberculosis: a Multicenter Randomized Controlled Study
The objective: to evaluate safety of Thiosonide in multiple doses, a new domestic anti-tuberculosis drug, in patients with multidrug, pre-extensively or extensively drug-resistant pulmonary tuberculosis.Subjects and Methods. The safety of Thiosonide was assessed from November 24, 2014 to May 17, 2019 within a multicenter, 12-week, double-blind, randomized, placebo-controlled clinical study (Protocol no. TIO22, Permit no. 661 dated November 24, 2014 by the Russian Ministry of Health). The study included 160 patients aged 18 to 60 years, who were undergoing inpatient or outpatient treatment in 13 clinical centers with the verified diagnosis of MDR TB, pre-XDR TB and XDR TB. Against the background of standard anti-tuberculosis therapy, patients received 200, 400 or 600 mg of Thiosonide or placebo once a day. Treatment duration made 84 days. The following parameters were used to assess safety of the drug: frequency and severity of adverse events (AEs) and serious adverse events (SAEs), number of cases of early discontinuation of the drug due AEs and SAEs, changes in vital signs during a physical examination, abnormal parameters of laboratory and instrumental tests and examinations.Results. It has been demonstrated that Thiosonide is well-tolerated and safe. During the study, 100 AEs were reported, but only one of them (1%), which was an elevated creatine phosphokinase level, was definitely related to the investigated drug. Statistical analysis reveal no significant relationship between the frequency of AEs and dosage of the drug.Conclusion. A safety study of Thiosonide, an original anti-tuberculosis drug, in patients with MDR, pre-XDR and XDR pulmonary TB with multiple administration in doses of 200 mg, 400 mg and 600 mg showed its good tolerability, accompanied by single AEs, of which no more than 1% were definitely related to the investigated drug. Due to the above, Thiosonide can be considered as a promising drug for the treatment of MDR/XDR TB patients.
- Open Access
- 15 August 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (3) , 147-159
Development and validation of esomeprazole magnesium trihydrate determination in workplace air using HPLC-MS/MS
Introduction. Esomeprazole is a proton pump inhibitor widely used in the treatment of acid-related diseases of the upper gastrointestinal tract. Upon inhalation exposure, it is classified as a substance of the highest hazard class, which requires monitoring its concentration in the workplace air at pharmaceutical enterprises. Despite the availability of methods for the quantitative analysis of esomeprazole in various matrices in the scientific literature, there are currently no methods for analyzing this substance in workplace or industrial air.Aim. To develop a method for the quantitative determination of esomeprazole magnesium trihydrate in workplace air using HPLC-MS/MS.Materials and methods. Air samples were collected using membrane filters with a diameter of 25 mm at a flow rate of 5,0 L/min. The analysis was performed using reference standards of esomeprazole magnesium trihydrate and carbamazepine. Chromatographic separation was carried out on a C18 column (2,5 μm, 100 × 4,6 mm). Detection was performed using a mass-selective detector in positive electrospray ionization mode by multiple reaction monitoring. MRM transitions were: 346,1 → 198,1 m/z for esomeprazole and 237,1 → 194,1 m/z for carbamazepine.Results and discussion. The method was validated according to the following parameters: suitability of the chromatographic system (the number of theoretical plates, N, for esomeprazole is at least 13170 and for carbamazepine, at least 5617), the asymmetry factor (As) for both substances does not exceed 1,36 and 1,41, respectively; limit of detection: 17 ng/mL; lower limit of quantification: 50 ng/mL; specificity (the response of interfering peaks for esomeprazole at most 1,2 % and for carbamazepine at most 0,25 %); linearity in the range of 50–5000 ng/mL (determination coefficient (R2) of at least 0,9995, accuracy from 92,8 to 106,1 %, and relative standard deviation (RSD, %) at most 4,2 %); intralaboratory accuracy (from 99,6 to 102,2 %) and interlaboratory accuracy (from 100,5 to 101,6 %); intralaboratory precision (RSD at most 4,3 %) and interlaboratory precision (RSD at most 5,8 %). All validation parameters met the acceptance criteria. The stability of esomeprazole on filters was confirmed for up to three months of storage.Conclusion. The development and implementation of the method enabled quantitative analysis of esomeprazole in workplace air and the assessment of the safety of the production process in accordance with hygienic requirements.
- 15 August 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (3) , 147-159
Open AccessDevelopment and validation of esomeprazole magnesium trihydrate determination in workplace air using HPLC-MS/MS
Introduction. Esomeprazole is a proton pump inhibitor widely used in the treatment of acid-related diseases of the upper gastrointestinal tract. Upon inhalation exposure, it is classified as a substance of the highest hazard class, which requires monitoring its concentration in the workplace air at pharmaceutical enterprises. Despite the availability of methods for the quantitative analysis of esomeprazole in various matrices in the scientific literature, there are currently no methods for analyzing this substance in workplace or industrial air.Aim. To develop a method for the quantitative determination of esomeprazole magnesium trihydrate in workplace air using HPLC-MS/MS.Materials and methods. Air samples were collected using membrane filters with a diameter of 25 mm at a flow rate of 5,0 L/min. The analysis was performed using reference standards of esomeprazole magnesium trihydrate and carbamazepine. Chromatographic separation was carried out on a C18 column (2,5 μm, 100 × 4,6 mm). Detection was performed using a mass-selective detector in positive electrospray ionization mode by multiple reaction monitoring. MRM transitions were: 346,1 → 198,1 m/z for esomeprazole and 237,1 → 194,1 m/z for carbamazepine.Results and discussion. The method was validated according to the following parameters: suitability of the chromatographic system (the number of theoretical plates, N, for esomeprazole is at least 13170 and for carbamazepine, at least 5617), the asymmetry factor (As) for both substances does not exceed 1,36 and 1,41, respectively; limit of detection: 17 ng/mL; lower limit of quantification: 50 ng/mL; specificity (the response of interfering peaks for esomeprazole at most 1,2 % and for carbamazepine at most 0,25 %); linearity in the range of 50–5000 ng/mL (determination coefficient (R2) of at least 0,9995, accuracy from 92,8 to 106,1 %, and relative standard deviation (RSD, %) at most 4,2 %); intralaboratory accuracy (from 99,6 to 102,2 %) and interlaboratory accuracy (from 100,5 to 101,6 %); intralaboratory precision (RSD at most 4,3 %) and interlaboratory precision (RSD at most 5,8 %). All validation parameters met the acceptance criteria. The stability of esomeprazole on filters was confirmed for up to three months of storage.Conclusion. The development and implementation of the method enabled quantitative analysis of esomeprazole in workplace air and the assessment of the safety of the production process in accordance with hygienic requirements.
- Open Access
- 7 May 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Potential targets for the new anti-tuberculosis drug of the diarylquinoline group thiozonide
Introduction. Diarylquinolines are considered a group of optimal candidates for anti-tuberculosis drugs (ATDs) in the treatment of tuberculosis caused by Mycobacterium tuberculosis exhibiting multidrug resistance.Aim. To perform a computer-aided analysis and evaluation of the potential molecular targets of the domestic anti-tuberculosis drug thiozonide using modern bioinformatics approaches.Material and methods. The SEA Search Service was employed to predict the drug targets. Based on the degree of chemical similarity calculated by the Tanimoto coefficient, this service predicts the effect of the investigated ligand on known targets. Compounds from the ChEMBL database were selected for the analysis, and structurally similar molecules were identified using the Tanimoto similarity measure. Possible targets of thiozonide were predicted using the PPB (Polypharmacology Browser for Target Prediction) service, which utilized six different fingerprints and four of their combinations. A significant potential of thiozonide to bind mycobacterial proteins, including those of M. tuberculosis, was revealed. Additionally, computer-based prediction of potential biological targets for thiozonide was carried out using the PPB (Polypharmacology Browser for Target Prediction in ChEMBL) service to analyze its polypharmacology. A search query initiated based on the chemical structure of thiozonide in SMILES format enabled the identification, among various targets listed in the ChEMBL database, of those most likely to interact with the studied compound.Results and discussion. According to the computer screening results, thiozonide demonstrated the most pronounced predicted activity against various representatives of the genus Mycobacterium, including M. tuberculosis. Based on the study findings, the most likely binding targets were the subunits of bacterial ATP synthase. This enzyme plays a central role in cellular energy metabolism by linking ATP synthesis and hydrolysis with proton translocation across the membrane. Although some human proteins were also identified as potential targets for thiozonide, the affinity of thiozonide to these human targets is considered rather low.Conclusion. The study results demonstrate the selective activity of thiozonide against mycobacteria, particularly M. tuberculosis strains. Thiozonide selectively interacts with the key subunits of the bacterial ATP synthase complex, thereby disrupting its catalytic function. Moreover, thiozonide exhibits low affinity towards human targets (affinity not exceeding 0.1).
- 7 May 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessPotential targets for the new anti-tuberculosis drug of the diarylquinoline group thiozonide
Introduction. Diarylquinolines are considered a group of optimal candidates for anti-tuberculosis drugs (ATDs) in the treatment of tuberculosis caused by Mycobacterium tuberculosis exhibiting multidrug resistance.Aim. To perform a computer-aided analysis and evaluation of the potential molecular targets of the domestic anti-tuberculosis drug thiozonide using modern bioinformatics approaches.Material and methods. The SEA Search Service was employed to predict the drug targets. Based on the degree of chemical similarity calculated by the Tanimoto coefficient, this service predicts the effect of the investigated ligand on known targets. Compounds from the ChEMBL database were selected for the analysis, and structurally similar molecules were identified using the Tanimoto similarity measure. Possible targets of thiozonide were predicted using the PPB (Polypharmacology Browser for Target Prediction) service, which utilized six different fingerprints and four of their combinations. A significant potential of thiozonide to bind mycobacterial proteins, including those of M. tuberculosis, was revealed. Additionally, computer-based prediction of potential biological targets for thiozonide was carried out using the PPB (Polypharmacology Browser for Target Prediction in ChEMBL) service to analyze its polypharmacology. A search query initiated based on the chemical structure of thiozonide in SMILES format enabled the identification, among various targets listed in the ChEMBL database, of those most likely to interact with the studied compound.Results and discussion. According to the computer screening results, thiozonide demonstrated the most pronounced predicted activity against various representatives of the genus Mycobacterium, including M. tuberculosis. Based on the study findings, the most likely binding targets were the subunits of bacterial ATP synthase. This enzyme plays a central role in cellular energy metabolism by linking ATP synthesis and hydrolysis with proton translocation across the membrane. Although some human proteins were also identified as potential targets for thiozonide, the affinity of thiozonide to these human targets is considered rather low.Conclusion. The study results demonstrate the selective activity of thiozonide against mycobacteria, particularly M. tuberculosis strains. Thiozonide selectively interacts with the key subunits of the bacterial ATP synthase complex, thereby disrupting its catalytic function. Moreover, thiozonide exhibits low affinity towards human targets (affinity not exceeding 0.1).
- Open Access
- 27 August 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Application of in vitro studies to predict the pharmacokinetics of rivaroxaban tablets
Introduction. The most important stage of pharmaceutical development of a generic drug is a clinical trial involving humans – a bioequivalence study. Considering the importance of finding rivaroxaban drugs in the list of vital and essential drugs, as part of ensuring technological sovereignty, the use of scientific robust and effective methods for determining the quality of the dosage form is required.Aim. Conduct a study of rivaroxaban tablets on a physiologically relevant tester to predict pharmacokinetic profiles.Materials and methods. The objects of the study are "Xarelto®, film-coated tablets, 10 mg" (series BXJS871, with an expiration date of October 31, 2024, Bayer AG, Germany), "Xarelto®, film-coated tablets, 20 mg" (series BXKDF32, with an expiration date of May 17, 2026, Bayer AG, Germany) and "Rivaroxaban, film-coated tablets, 10 mg" and "Rivaroxaban, film-coated tablets, 20 mg", domestically produced, with valid expiration dates. During the study, reagents were used to prepare dissolution media and perform quantitative determination. The physiologically relevant test was performed on the SC PRT-6 device (LLC "Scientific Compliance", Russia). The quantitative content of released rivaroxaban within the comparative dissolution kinetics test in a medium of 0.1 in a medium of 0.1 % sodium lauryl sulfate solution in a phosphate buffer solution pH 6.5 was carried out on a SF-2000 spectrophotometer (LLC "OKB Spektr", Russia). The quantitative content of released rivaroxaban within the comparative dissolution kinetics test in biorelevant dissolution media and physiological relevance test was assessed on a high-performance liquid chromatograph "Chromatec-Crystal HPLC 2014" (CJSC "Chromatec", Russia). Pharmacokinetic profiles were modeled in the PK-Sim® (Systems Biology Software Suite 11.2, Bayer Technology Services GmbH, Germany) program based on the data obtained within the physiologically relevant test. The clinical study of rivaroxaban tablets was a prospective, open-label, randomized, crossover, two-stage comparative study in two groups of volunteers with a single dose of drugs on the fast condition. The study randomized 30 healthy male volunteers aged 18–45 years.Results and discussion. A complex of in vitro tests was conducted, profiles were obtained that allow us to evaluate the dynamics and degree of release of the studied drugs in various parts of the human gastrointestinal tract. A comparison of the sequential and hybrid schemes for conducting the physiological relevance test was carried out. Within the framework of the set of tests, qualitative and quantitative correlation with the clinical trials data was observed only for the hybrid physiological relevance test scheme. Based on the results of physiological relevance test using different schemes, pharmacokinetic profiles for a pair of drugs were predicted and the prediction error was assessed.Conclusion. A set of scientific in vitro tests was conducted for the drugs "Xarelto®, film-coated tablets, 10 mg and 20 mg", "Rivaroxaban, film-coated tablets, 10 mg and 20 mg". Based on the physiological relevance test results, pharmacokinetic profiles for a pair of drugs were predicted with low error and high reliability. As part of the comparison of data obtained during clinical trial and modeling, the smallest prediction error was noted when performing physiological relevance test using a hybrid scheme.
- 27 August 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessApplication of in vitro studies to predict the pharmacokinetics of rivaroxaban tablets
Introduction. The most important stage of pharmaceutical development of a generic drug is a clinical trial involving humans – a bioequivalence study. Considering the importance of finding rivaroxaban drugs in the list of vital and essential drugs, as part of ensuring technological sovereignty, the use of scientific robust and effective methods for determining the quality of the dosage form is required.Aim. Conduct a study of rivaroxaban tablets on a physiologically relevant tester to predict pharmacokinetic profiles.Materials and methods. The objects of the study are "Xarelto®, film-coated tablets, 10 mg" (series BXJS871, with an expiration date of October 31, 2024, Bayer AG, Germany), "Xarelto®, film-coated tablets, 20 mg" (series BXKDF32, with an expiration date of May 17, 2026, Bayer AG, Germany) and "Rivaroxaban, film-coated tablets, 10 mg" and "Rivaroxaban, film-coated tablets, 20 mg", domestically produced, with valid expiration dates. During the study, reagents were used to prepare dissolution media and perform quantitative determination. The physiologically relevant test was performed on the SC PRT-6 device (LLC "Scientific Compliance", Russia). The quantitative content of released rivaroxaban within the comparative dissolution kinetics test in a medium of 0.1 in a medium of 0.1 % sodium lauryl sulfate solution in a phosphate buffer solution pH 6.5 was carried out on a SF-2000 spectrophotometer (LLC "OKB Spektr", Russia). The quantitative content of released rivaroxaban within the comparative dissolution kinetics test in biorelevant dissolution media and physiological relevance test was assessed on a high-performance liquid chromatograph "Chromatec-Crystal HPLC 2014" (CJSC "Chromatec", Russia). Pharmacokinetic profiles were modeled in the PK-Sim® (Systems Biology Software Suite 11.2, Bayer Technology Services GmbH, Germany) program based on the data obtained within the physiologically relevant test. The clinical study of rivaroxaban tablets was a prospective, open-label, randomized, crossover, two-stage comparative study in two groups of volunteers with a single dose of drugs on the fast condition. The study randomized 30 healthy male volunteers aged 18–45 years.Results and discussion. A complex of in vitro tests was conducted, profiles were obtained that allow us to evaluate the dynamics and degree of release of the studied drugs in various parts of the human gastrointestinal tract. A comparison of the sequential and hybrid schemes for conducting the physiological relevance test was carried out. Within the framework of the set of tests, qualitative and quantitative correlation with the clinical trials data was observed only for the hybrid physiological relevance test scheme. Based on the results of physiological relevance test using different schemes, pharmacokinetic profiles for a pair of drugs were predicted and the prediction error was assessed.Conclusion. A set of scientific in vitro tests was conducted for the drugs "Xarelto®, film-coated tablets, 10 mg and 20 mg", "Rivaroxaban, film-coated tablets, 10 mg and 20 mg". Based on the physiological relevance test results, pharmacokinetic profiles for a pair of drugs were predicted with low error and high reliability. As part of the comparison of data obtained during clinical trial and modeling, the smallest prediction error was noted when performing physiological relevance test using a hybrid scheme.